Polycystic ovary syndrome is not an approved use for Zepbound, yet insulin resistance ties the two together. This overview explains the GIP/GLP-1 dual mechanism, what published trials measured, the safety profile, and how genetic pathway context frames any conversation with a clinician.

PCOS is not a current FDA-approved indication for GLP-1 receptor agonists, and this article frames that honestly. It covers the semaglutide molecule, the insulin-resistance rationale behind off-label discussion, the trial evidence clinicians consult, the safety limits, and the inherited traits that shape metabolic biology.